Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products…more
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products…more
Latest RNS from Hikma Pharmaceuticals PLC
- director_pdmrDirector/PDMR Shareholding
- Hikma appoints Umang Vohra as a Director
- trading_updateTrading Statement
- board_changeDirectorate change
- interim_resultsHalf-year Financial Report
Analyst consensus: Buy
As of 10 Nov 2026, 12 analysts rate Hikma Pharmaceuticals PLC a Buy, with 92% buy ratings and a mean price target of 1,982p (range 1,693p–2,634p), +22% vs the current price.
Valuation vs peers
Peer-relative fair value estimate: 2,635p against a current price of 1,635p (+61%), based on EV/EBITDA.